32 related articles for article (PubMed ID: 9562232)
1. Mycophenolate Metabolite Trough Concentrations Are Not Well Correlated With Dosing or Adverse Outcomes in Pediatric Heart Transplant Recipients.
Saad MS; Chen J; Salerno D; Corbo H
J Pediatr Pharmacol Ther; 2024 Jun; 29(3):299-305. PubMed ID: 38863858
[TBL] [Abstract][Full Text] [Related]
2. Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients.
Sheng C; Zhao Q; Niu W; Qiu X; Zhang M; Jiao Z
Front Pharmacol; 2020; 11():340. PubMed ID: 32265712
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota biotransformation of drug glucuronides leading to gastrointestinal toxicity: Therapeutic potential of bacterial β-glucuronidase inhibition in mycophenolate-induced enteropathy.
Brossier C; Jardou M; Janaszkiewicz A; Firoud D; Petit I; Arnion H; Pinault E; Sauvage FL; Druilhe A; Picard N; Di Meo F; Marquet P; Lawson R
Life Sci; 2024 Jun; 351():122792. PubMed ID: 38857657
[TBL] [Abstract][Full Text] [Related]
4. Elimination and penetration of amikacin into urine in patients with decreased glomerular filtration rate.
Hartinger JM; Dvořáčková E; Krátký V; Hrušková Z; Mysliveček M; Bobek D; Benáková H; Závora J; Kroneislová G; Halouzková BA; Brejníková M; Martínková V; Tesař V; Slanař O
Clin Kidney J; 2024 Jan; 17(1):sfae002. PubMed ID: 38260825
[TBL] [Abstract][Full Text] [Related]
5. Developmental changes of MPA exposure in children.
Yoo EC; Alvarez-Elías AC; Todorova EK; Filler G
Pediatr Nephrol; 2016 Jun; 31(6):975-82. PubMed ID: 26743220
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis.
Morgera S; Budde K; Lampe D; Ahnert V; Fritsche L; Kuchinke S; Neumayer HH
Transpl Int; 1998; 11(1):53-7. PubMed ID: 9503555
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
[TBL] [Abstract][Full Text] [Related]
9. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
10. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
Merkel U; Lindner S; Vollandt R; Sperschneider H; Balogh A
Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis.
Morgera S; Neumayer HH; Fritsche L; Kuchinke S; Lampe D; Ahnert V; Bauer S; Mai I; Budde K
Int J Clin Pharmacol Ther; 1998 Mar; 36(3):159-63. PubMed ID: 9562232
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
